Significant biosimilar activities this week include:
22 March 2023 | US | PTAB institutes Celltrion and Samsung IPRs re Regeneron’s key aflibercept patents
21 March 2023 | CN | China’s NMPA accepts BLA for Boan Biotech’s biosimilar to Amgen’s Xgeva® (denosumab)
21 March 2023 | US | AbbVie Humira empire spirals as FDA approves Sandoz adalimumab biosimilar Hyrimoz®
21 March 2023 | EU | New Indication Alert: EC approves Regeneron / Sanofi’s Dupixent® (dupilumab) for children 6 months+
15 March 2023 | CN | Janssen’s redacted public brief in support of preliminary injunction regarding Amgen’s Stelara® (ustekinemab) biosimilar